Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett Sells 5,162 Shares of Stock

Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett sold 5,162 shares of Immunovant stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $29.56, for a total transaction of $152,588.72. Following the completion of the transaction, the chief financial officer now directly owns 338,614 shares in the company, valued at $10,009,429.84. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Eva Renee Barnett also recently made the following trade(s):

• On Wednesday, July 17th, Eva Renee Barnett sold 3,123 shares of Immunovant stock. The stock was sold at an average price of $29.69, for a total transaction of $92,721.87.

Immunovant Price Performance

NASDAQ IMVT opened at $30.40 on Friday. The company has a market capitalization of $4.45 billion, a PE ratio of -15.75 and a beta of 0.66. The company has a fifty day moving average of $29.95 and a 200 day moving average of $29.08. Immunovant, Inc. has a 1 year low of $24.67 and a 1 year high of $45.58.

Immunovant (NASDAQ:IMVT) last posted its earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.07). During the same quarter in the prior year, the business posted ($0.57) EPS. Research analysts expect that Immunovant, Inc. will post -2.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Oppenheimer lifted their price target on shares of Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $51.00 price target on shares of Immunovant in a report on Monday, September 30th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunovant in a report on Monday, September 9th. JPMorgan Chase & Co. dropped their price objective on shares of Immunovant from $51.00 to $46.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Finally, Raymond James reissued an “outperform” rating and set a $36.00 price objective on shares of Immunovant in a report on Thursday. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunovant presently has an average rating of “Buy” and an average price target of $48.58.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. DNB Asset Management AS increased its stake in shares of Immunovant by 10.3% during the second quarter. DNB Asset Management AS now owns 10,290 shares of the company’s stock worth $271,000 after purchasing an additional 958 shares in the last quarter. Bamco Inc. NY increased its stake in shares of Immunovant by 1.7% during the first quarter. Bamco Inc. NY now owns 60,000 shares of the company’s stock worth $1,939,000 after purchasing an additional 1,000 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Immunovant by 9.4% during the first quarter. ProShare Advisors LLC now owns 19,877 shares of the company’s stock worth $642,000 after purchasing an additional 1,703 shares in the last quarter. Quest Partners LLC increased its stake in shares of Immunovant by 216.7% during the second quarter. Quest Partners LLC now owns 2,610 shares of the company’s stock worth $69,000 after purchasing an additional 1,786 shares in the last quarter. Finally, Sei Investments Co. increased its stake in shares of Immunovant by 11.2% during the first quarter. Sei Investments Co. now owns 20,690 shares of the company’s stock worth $668,000 after purchasing an additional 2,085 shares in the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.